期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 59, 期 3, 页码 1802-1805出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.04809-14
关键词
-
资金
- Tetraphase Pharmaceuticals, Inc.
Eravacycline demonstrated in vitro activity against a contemporary collection of more than 4,000 Gram-negative pathogens from New York City hospitals, with MIC50/MIC90 values, respectively, for Escherichia coli of 0.12/0.5 mu g/ml, Klebsiella pneumoniae of 0.25/1 mu g/ml, Enterobacter aerogenes of 0.25/1 mu g/ml, Enterobacter cloacae 0.5/1 mu g/ml, and Acinetobacter baumannii of 0.5/1 mu g/ml. Activity was retained against multidrug-resistant isolates, including those expressing KPC and OXA carbapenemases. For A. baumannii, eravacycline MICs correlated with increased expression of the adeB gene.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据